Bellerophon reports reports FY22 EPS ($2.08) vs ($1.87) last year

"We have achieved significant recent progress throughout our business, including advancing the INOpulse(R) clinical program, enhancing our regulatory and commercial prospects in China, and strengthening the balance sheet," said Peter Fernandes, Bellerophon’s Chief Executive Officer. "With the INOpulse REBUILD Phase 3 study fully enrolled, we anticipate treating the last patient in the second quarter of 2023, followed by pivotal top-line data readout in mid-2023. Moreover, the recent license agreement established with Baylor BioSciences and the IND clearance from China NMPA to conduct a Phase 3 clinical trial in fibrotic interstitial lung disease position us well to access one of the largest commercial markets globally. Importantly, following the license agreement with Baylor and successfully completed $5 million financing, we are now well-capitalized through top-line data from the pivotal Phase 3 REBUILD trial."